When you have a thereapeutic that works, actually works, you don’t need 40,000 subjects to “prove” it. You just need a few hundred people actually at risk. You don’t need to play games with how you classify illness. Or to blow up your clinical trial by destroying the placebo as soon as you get “authorization.”
You don’t need annual or more “boosters” (for a “vaccine”!).
And you don’t need free lotteries or mandates or anything else to dupe or force people to take it.
You just need a drug that works.
Merck makes drugs that work. (Not always, but more than anyone else.)
KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19. At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14.1% of placebo-treated patients (53/377); p=0.0012. Through Day 29, no deaths were reported in patients who received molnupiravir, as compared to 8 deaths in patients who received placebo…